No abstract available.
Child* ; Humans ; Scrub Typhus*

No Abstract available.
Mucocutaneous Lymph Node Syndrome*

No abstract available.
Meningitis* ; Meningitis, Viral*

No abstract available.
Animals* ; Models, Animal* ; Mucocutaneous Lymph Node Syndrome*

Kawasaki disease (KD) was first described by Dr. Tomisaku Kawasaki in his 1975 study, published in Pediatrics. Its pathogenesis is still not clearly understood. Early diagnosis and treatment are very important to preventing concomitant coronary artery complications. Most KD patients respond well to the standard treatment of aspirin and intravenous immunoglobulin; however, some of them are refractory to the standard treatment, and so adjuvant therapies with corticosteroids and anti-tumor necrosis factor-alpha (TNF-alpha) antibody are necessary. In this article, the author reviews and summarizes the most recent literature on the treatment of refractory KD.
Adrenal Cortex Hormones ; Aspirin ; Coronary Vessels ; Early Diagnosis ; Humans ; Mucocutaneous Lymph Node Syndrome ; Necrosis ; Pediatrics

Kawasaki disease (KD) is a systemic vasculitis of unknown etiology in young children. There has been many trials to find out the causes of KD all over the world since Dr. Kawasaki published the first KD cases in Pediatrics (1973). The studies using animal models have been carried out noticablly in Japan and North America, initiated by Dr. Murata (1979) and Dr. Lehman (1985). The medical doctors and scientists have used many animals for their studies, for example, dog, rabbit, swine and mice. Nowadays, mice is the most popular animal model for patho-physiologic research of KD. However, there is no report about animal model research of KD in Korea. I emphasize that we have to start to search the causes of KD through experimental trials. Candida albicans extract and Lactobacillus casei cell wall extract were used to make coronary arteritis in animal models as in case of KD in humans. Recently, there is a good result in developing new drugs (TNF-alpha blockade) for the treatment of KD patients who are resistant to intravenous immunoglobulin and methylprednisolone through animal model research of KD.
Animals* ; Arteritis ; Candida albicans ; Cell Wall ; Child ; Dogs ; Humans ; Immunoglobulins ; Japan ; Korea ; Lactobacillus casei ; Methylprednisolone ; Mice ; Models, Animal* ; Mucocutaneous Lymph Node Syndrome* ; North America ; Pediatrics ; Swine ; Systemic Vasculitis

No abstract available.
Humans ; Infant, Newborn*

No abstract available.
Diagnosis* ; Mucocutaneous Lymph Node Syndrome*

Kawasaki disease (KD) has been increasing recently in Korea. Although the delayed diagnosis of KD can cause coronary artery abnormalities, no specific test is available. Thus, optimal guidelines for early diagnosis and treatment of KD are the best way to prevent the development of coronary artery abnormalities. The 2017 updated American Heart Association guidelines for diagnosis, treatment, and long-term management of KD are informative for physicians who face with children having manifestations suggestive of KD.
American Heart Association ; Aneurysm ; Child ; Coronary Vessels ; Delayed Diagnosis ; Diagnosis ; Early Diagnosis ; Humans ; Korea ; Mucocutaneous Lymph Node Syndrome ; Secondary Prevention

No abstract available.
Dyskeratosis Congenita*